Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

BioNTech plans to further investigate the drug’s potential in combination with mRNA vaccines, targeted therapies and ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

BioNTech adds bispecific candidate, mRNA delivery startup as cancer work takes center stage The opportunity is enormous: ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Florida Gov. Ron DeSantis is advocating for President-elect Donald Trump to tap Florida Surgeon General Joseph Ladapo for the role of HHS secretary.

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Moderna's Spikevax COVID vaccine brought in sales of $1.8 billion, up 3.5% over the previous year and handily beating analysts' average expectations of $1.38 billion. The company said it benefited ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...